Article Text
Other content recommended for you
- Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease
- Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up
- Parkinson’s disease: etiopathogenesis and treatment
- Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies
- What to do when people with Parkinson's disease cannot take their usual oral medications
- Response of parkinsonian swallowing dysfunction to dopaminergic stimulation
- When the going gets tough: how to select patients with Parkinson's disease for advanced therapies
- Drugs for Parkinson’s disease
- Deep brain stimulation of the subthalamic nucleus: effectiveness in advanced Parkinson’s disease patients previously reliant on apomorphine
- Developments in the treatment of Parkinson's disease